Interview with Jean Marimbert, Director General, Agence Française de Sécurité…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
Alfa Wassermann is a pharmaceutical group with an Italian heart and an international outlook. For over sixty years, it has researched, manufactured and distributed drugs of primary importance for human health, allowing people to benefit from new discoveries in medicine, biology and genomics. Today the Group operates in 12 different countries and employs approximately 1,370 employees, 670 of which in Italy.
Alfa Wassermann´s strategy is to focus on the gastro-intestinal area. Already present in IBS, constipation and diarrhoea, with the launch of Rifaximin-alpha 500 they will be active in a further major gastro-intestinal related area, namely hepatic encephalopathy. In France market authorization was received for Rifaximin-alpha 500mg in January 2015. Alfa Wassermann and its partner Norgine will jointly promote and manage the clinical development of Rifaximine alpha 550 mg in France.
Contact
ALFA WASSERMANN PHARMA SAS
67, rue Anatole France
92300 Levallois Perret – France
Ph. +33 1 41 27 25 10 – Fax +33 1 47 58 77 04
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative…
What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that…
See our Cookie Privacy Policy Here
